Clinical trials: Glial Tumor
Glioblastoma
Anti-GITR/Anti-PD1/Stereotactic Radiosurgery, in Recurrent Glioblastoma
This is a phase II study of the combination of the GITR agonist monoclonal antibody INCAGN01876, the anti-PD1 monoclonal antibody INCMGA00012, and stereotactic radiosurgery (SRS) for recurrent Glioblastoma (GBM).
- Trial name
- NCT04225039
- Testing
- INCMGA00012, INCAGN01876, SRS
- Where
- United States
- Volunteers
- 39 people
- Sponsor
- University of Pennsylvania
Glioma
rhIL-7-hyFc on Increasing Lymphocyte Counts in Patients With Newly Diagnosed Non-severe Lymphopenic Gliomas Following Radiation and Temozolomide
The investigators have developed a phase I/II clinical trial to evaluate the effect of rhIL-7-hyFc on lymphocyte counts in patients with high grade glioma (HGG).
- Trial name
- NCT03687957
- Testing
- rhIL-7-hyFc, Temozolomide, Radiation therapy
- Where
- United States
- Volunteers
- 42 people
- Sponsor
- Washington University School of Medicine
Solid Tumour, Haematological Malignancy
DETERMINE Trial Treatment Arm 06: Capmatinib in Adult Patients With Cancers Harbouring MET Dysregulations
This clinical trial is looking at a drug called capmatinib. Capmatinib is approved as standard of care treatment for adult patients with certain types of lung cancer.
- Conditions
- Solid Tumour, Haematological Malignancy, Malignant Neoplasm, Neoplasms by Histologic Type
- Trial name
- DETERMINE (NCT06988475)
- Testing
- Capmatinib
- Where
- 17 sites in United Kingdom
- Volunteers
- 30 people
- Sponsor
- Cancer Research UK
Brain and Central Nervous System Tumors, Melanoma (Skin)
Boron Neutron Capture Therapy in Treating Patients With Glioblastoma Multiforme or Melanoma Metastatic to the Brain
RATIONALE: Radiation therapy such as boron neutron capture therapy may kill tumor cells without harming normal tissue. PURPOSE: Phase I/II trial to study the effectiveness of boron neutron capture therapy in treating patients who…
- Conditions
- Brain and Central Nervous System Tumors, Melanoma (Skin), Metastatic Cancer
- Trial name
- NCT00039572
- Testing
- boronophenylalanine-fructose complex
- Where
- 2 sites in United States
- Sponsor
- Beth Israel Deaconess Medical Center
Glioblastoma, GBM
LY3214996 Plus Abemaciclib in Recurrent Glioblastoma Patients
This trial is an open-label, multicenter, Phase 0/2 trial that will enroll up to 50 participants with recurrent glioblastoma which are schedule for resection.
- Conditions
- Glioblastoma, GBM, Glioma
- Trial name
- NCT04391595
- Testing
- Abemaciclib, LY3214996
- Where
- 3 sites in United States
- Volunteers
- 42 people
- Sponsor
- Nader Sanai
Glioblastoma, Gliosarcoma
Study of Lenalidomide and XRT in Patients With Newly Diagnosed Glioblastoma Multiforme
The purpose of this study is to find out if the combination of lenalidomide and radiation therapy is effective in controlling tumor growth in patients with newly-diagnosed supratentorial glioblastoma or gliosarcoma.
- Conditions
- Glioblastoma, Gliosarcoma, Malignant Gliomas
- Trial name
- NCT00165477
- Testing
- lenalidomide, Radiation
- Where
- 4 sites in United States
- Volunteers
- 23 people
- Sponsor
- Dana-Farber Cancer Institute
Glioblastoma, Glioblastoma Multiforme (GBM)
Patient's Derived Organoids for Drug Screening in Glioblastoma
The study will enroll patients suffering from glioblastoma, a malignant brain tumor. Intervention is intended as a laboratory intervention and not as a clinical intervention.
- Conditions
- Glioblastoma, Glioblastoma Multiforme (GBM), Glioblastoma Multiforme, Adult
- Trial name
- GlioPDO (NCT06781372)
- Testing
- Development and characterization of PDOs, Evaluation of the effects of epigenetic and splicing inhibitors on viability and gene expression signatures of GBM PDOs and GSCs
- Where
- Italy
- Volunteers
- 100 people
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Glioblastoma, Brain Tumors
Assessment of Early Post-operative Nuclear Imaging in Neurosurgery: a Safety and Feasibility Study in Patients Operated for Glioblastoma
This clinical trial aims to evaluate the feasibility and safety of early post-operative brain PET-MRI imaging in adult patients who have undergone surgery for suspected glioblastoma.
- Conditions
- Glioblastoma, Brain Tumors, Brain Imaging
- Trial name
- EARLYBRAINPET (NCT07274397)
- Testing
- Early post-operative brain PET-MRI with 18F-DOPA and Gadolinium
- Where
- France
- Volunteers
- 15 people
- Sponsor
- Beta Emitting Accurate Monitored Systems
Low-grade Glioma
Rehabilitation and Longitudinal Follow-up of Cognition in Adult Lower Grade Gliomas
Patients with glial brain tumors have increasingly improved outcomes, with median survival of 5-15 years. However, the treatments, including surgery, radiation, and chemotherapy, often lead to impaired attention, working memory…
- Trial name
- NCT03948490
- Testing
- ReMind iPad app, Healthy SMS texting, In-person cognitive rehabilitation
- Where
- United States
- Volunteers
- 117 people
- Sponsor
- University of California, San Francisco
High-grade Glioma
Study of MT027 in Patients with Recurrent or Progressive High-grade Glioma
The clinical protocol plans to preset three dose groups, namely 1×10⁷ cells per dose, 3×10⁷ cells per dose, and 6×10⁷ cells per dose.
- Trial name
- NCT06737146
- Testing
- MT027 cells suspension
- Where
- China
- Volunteers
- 12 people
- Sponsor
- Suzhou Maximum Bio-tech Co., Ltd.
Glioblastoma Multiforme, Gliosarcoma
Zactima With Temodar During Radiation Treatment for Newly Diagnosed Stage IV Brain Tumors
Phase I: The purpose of this research study is to determine the safety of the combination treatment of ZD6474 (Vandetanib) with the standard therapy for glioblastomas and gliosarcomas, temozolomide (Temodar) and radiation…
- Trial name
- Zactima (NCT00441142)
- Testing
- ZD6474, temozolomide, Radiation Therapy
- Where
- 7 sites in United States
- Volunteers
- 119 people
- Sponsor
- Patrick Y. Wen, MD
Glioblastoma, Newly Diagnosed Glioblastoma
REMIND Maintenance Radiotherapy for Newly Diagnosed Glioblastoma
REMIND is a single-center feasibility study testing maintenance radiotherapy in adult patients with newly diagnosed glioblastoma.
- Conditions
- Glioblastoma, Newly Diagnosed Glioblastoma, Brain Tumor
- Trial name
- REMIND (NCT07831772)
- Testing
- Maintenance Radiotherapy
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- University of Minnesota
IDH Wildtype Glioblastoma, Glioblastoma (GBM)
Biomarker-guided RAdiation-deferring Treatment in Younger GBM Patients - Pilot Study
This study will investigate whether rapid molecular testing of recurrent glioblastoma (GBM) can identify tumour biomarkers that may help guide treatment selection in younger people with IDH-wildtype GBM.
- Trial name
- BRAid GBM (NCT07908147)
- Testing
- Larotrectinib, Cadonilimab, Plixorafenib
- Where
- Australia
- Volunteers
- 12 people
- Sponsor
- Olivia Newton-John Cancer Research Institute
Glioma, Glioblastoma Multiforme
Genetic Analysis of Brain Tumors
This study will analyze tissue and blood samples from patients with gliomas (a type of brain tumor) to develop a new classification system for these tumors.
- Conditions
- Glioma, Glioblastoma Multiforme, Anaplastic Astrocytoma, Oligodendroglioma
- Trial name
- NCT00031538
- Where
- 3 sites in United States
- Volunteers
- 674 people
- Sponsor
- National Cancer Institute (NCI)
Brain Tumor, Primary, Brain Tumor, Recurrent
Performance of Elucirem in DSC-MRI Perfusion of Brain Gliomas
This trial aimed to study the performance of Elucirem (gadopiclenol) in Dynamic Susceptibility Contrast Magnetic Resonance Imaging (DSC-MRI) perfusion of brain gliomas.
- Trial name
- GDX-44-016 (NCT06057168)
- Testing
- Elucirem, Dotarem
- Where
- 11 sites in Hungary, Italy and 1 more
- Volunteers
- 138 people
- Sponsor
- Guerbet
Glioblastoma
Assessment of Safety and Feasibility of ExAblate Blood-Brain Barrier (BBB) Disruption for Treatment of Glioma
The purpose of this study is to evaluate the safety of blood-brain barrier (BBB) disruption in adult patients with a first presentation of a glioblastoma (GBM) following a maximal safe surgical resection and standard…
- Trial name
- NCT03616860
- Testing
- Focused Ultrasound (FUS) BBB Disruption
- Where
- Canada
- Volunteers
- 14 people
- Sponsor
- InSightec
Glioblastoma (GBM)
A Phase 1/2 Study of the Safety and Tolerability of MT-125 in GBM Patients
The purpose of the study is to determine the recommended dose and further understand the safety of MT-125 in participants who have been diagnosed with glioblastoma, a primary brain tumor, when administered in combination with…
- Trial name
- STAR-GBM (NCT07185880)
- Testing
- MT-125
- Where
- 3 sites in United States
- Volunteers
- 36 people
- Sponsor
- Myosin Therapeutics Inc.
Glioblastoma Multiforme
Concomitant Association of Ultrafractionated Brain Irradiation - Temozolomide in Inoperable Primary Glioblastoma Multiforme
The main purpose of this study is the evaluation of concomitant association of ultrafractionated irradiation and Temodal® in patients with inoperable primary glioblastoma multiforme; study of tolerance and objective response…
- Trial name
- TEMOFRAC (NCT03310372)
- Testing
- Ultrafractionated brain irradiation, Temozolomide
- Volunteers
- 46 people
- Sponsor
- Central Hospital, Nancy, France
Glioblastoma Multiforme
Trial of Temozolomide, Bevacizumab Plus Bortezomib for Recurrent Glioblastoma Multiforme
This is a single-center (Emory University), open-label, single arm, phase I study to assess safety and toxicity of bortezomib in combination with bevacizumab and escalating doses of temozolomide for patients with recurrent…
- Trial name
- NCT01435395
- Testing
- Temozolomide, bevacizumab and bortezomib
- Where
- 2 sites in United States
- Volunteers
- 12 people
- Sponsor
- Emory University
Glioblastoma, Gliosarcoma
Phase I Trial of DNA-PK Inhibitor (PEPOSERTIB ) in Combination With Radiation and Adjuvant Temozolomide in Newly Diagnosed MGMT Unmethylated and Recurrent Glioblastoma
This phase I trial investigates the side effects and best dose of Peposertib, and to see how well it works in combination with radiation therapy in treating patients with newly diagnosed MGMT unmethylated glioblastoma or…
- Trial name
- NCT04555577
- Testing
- Peposertib, Radiation Therapy, Resection
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- M.D. Anderson Cancer Center
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.